Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure

TriHealth

Status: Not yet enrolling

Conditions: Human Immunodeficiency Virus

Treatments: Dietary Supplement: Nicotinamide Mononucleotide

Study type: Interventional

Funder types: Other

Identifiers

NCT06889142

24-089

Details and patient eligibility

About

This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppressed HIV patients experiencing immunological failure on ART. We hypothesize that NMN supplementation will increase intracellular NAD+ levels, thereby improving CD4+ T cell function and potentially reversing immunological failure. A small cohort of patients will be recruited to evaluate the primary outcome of change in CD4+ T cell count from baseline to the end of the study period after receiving NMN daily for 12 weeks. Secondary outcomes including safety and tolerability, impact on pro-inflammatory markers, increase in NAD+ levels, immune activation markers and change in quality of life questionnaire scores. Patients will participate in two in person visits including a baseline and end of study with two telephone encounters. Patients will take 1,000mg NMN daily for a total of 12 weeks during which they will keep a daily log of doses taken and any side effects experienced. At all visits labs and quality of life questionnaire will be completed with complete physical exam to be done at baseline and end of study visit.

Enrollment: 7 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-infected adults aged 18 years or older
• Virologically suppressed on ART documented with two negative viral loads separated by at least 6 months
• Confirmed diagnosis of immunological failure (CD4+ T cell count <350 cells/µL 2 years after effective ART initiation)
• Willing to provide informed consent

Exclusion criteria

• Active opportunistic infections
• Known allergies or sensitivities to NMN or any components of the NMN supplement
• Current or recent use of other supplements or medications known to affect NAD+ metabolism (Niacin, NR, NMNH, etc.)
• Pregnancy or breastfeeding
• Significant liver or kidney disease
• Active malignancy
• History of uncontrolled substance abuse
• Severe medical conditions that might interfere with study participation
• Unable to consent

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

Treatment with 1,000mg Nicotinamide Mononucleotide daily

Experimental group

Treatment:

Dietary Supplement: Nicotinamide Mononucleotide